Christopher Ryan Sullivan
Chief Financial Officer · 11 filings · Latest: Sep 16, 2026
Avalo Therapeutics, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
AVTX | Christopher Ryan Sullivan | Chief Financial Officer | Apr 2, 2026 | Sale | $17.15 | 7,980 | $136.8K | 17,338 | |
AVTX | Christopher Ryan Sullivan | Chief Financial Officer | Apr 1, 2026 | Sale | $16.77 | 7,979 | $133.8K | 25,318 | |
AVTX | CHRISTOPHER SULLIVAN | — | Apr 1, 2026 | Proposed Sale | $14.93 | 15,959 | $238.3K | — | |
AVTX | Christopher Ryan Sullivan | Chief Financial Officer | Mar 28, 2026 | Option Exercise | — | 24,200 | — | 41,538 |
← Previous
Page 2 of 2